Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · see citing works

Fast and accurate short read alignment with Burrows-Wheeler transform

Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607 · see citing works

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · see citing works

Enrichr: a comprehensive gene set enrichment analysis web server 2016 update

Kuleshov, M. V., Jones, M. R., Rouillard, A. D., Fernandez, N. F., Duan, Q., Wang, Z., Koplev, S., Jenkins, S. L., Jagodnik, K. M., Lachmann, A., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw377 · Cited by 10,799 · see citing works

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078 · see citing works

VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencingPreprint

Koboldt, D. C., Zhang, Q., Larson, D. E., Shen, D., McLellan, M. D., Lin, L., Miller, C. A., Mardis, E. R., Ding, L., & Wilson, R. K. (2012) · Genome Research · doi:10.1101/gr.129684.111 · Cited by 4,822 · see citing works

Identification of a Primary Target of Thalidomide Teratogenicity

Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136 · see citing works

Fast and SNP-tolerant detection of complex variants and splicing in short reads

Wu, T. D., & Nacu, S. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq057 · Cited by 1,894 · see citing works

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma

Morin, R. D., Mendez-Lago, M., Mungall, A. J., Goya, R., Mungall, K. L., Corbett, R. D., Johnson, N. A., Severson, T. M., Chiu, R., Field, M., et al. (2011) · Nature · doi:10.1038/nature10351 · Cited by 1,614 · see citing works

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583 · see citing works

Using Drosophila melanogaster as a Model for Genotoxic Chemical Mutational Studies with a New Program, SnpSift

Cingolani, P., Patel, V. M., Coon, M., Nguyen, T. T., Land, S. J., Ruden, D. M., & Lu, X. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00035 · Cited by 1,012 · see citing works

RNA-SeQC: RNA-seq metrics for quality control and process optimization

DeLuca, D. S., Levin, J. Z., Sivachenko, A., Fennell, T., Nazaire, M.-D., Williams, C., Reich, M., Winckler, W., & Getz, G. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts196 · Cited by 899 · see citing works

Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS

Krönke, J., Fink, E. C., Hollenbach, P. W., MacBeth, K. J., Hurst, S. N., Udeshi, N. D., Chamberlain, P. P., Mani, D. R., Man, H. W., Gandhi, A. K., et al. (2015) · Nature · doi:10.1038/nature14610 · Cited by 863 · see citing works

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Van Wier, S., Chang, X.-B., Bjorklund, C. C., Fonseca, R., Bergsagel, P. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-356063 · Cited by 607 · see citing works

Sailfish enables alignment-free isoform quantification from RNA-seq reads using lightweight algorithms

Patro, R., Mount, S. M., & Kingsford, C. (2014) · Nature Biotechnology · doi:10.1038/nbt.2862 · Cited by 586 · see citing works

<i>TP53</i> Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression

Jädersten, M., Saft, L., Smith, A., Kulasekararaj, A., Pomplun, S., Göhring, G., Hedlund, A., Hast, R., Schlegelberger, B., Porwit, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8576 · Cited by 463 · see citing works

Early hematopoietic lineage restrictions directed by Ikaros

Yoshida, T., Ng, S. Y., Zúñiga‐Pflücker, J. C., & Georgopoulos, K. (2006) · Nature Immunology · doi:10.1038/ni1314 · Cited by 324 · see citing works

Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting

He, J., Abdel-Wahab, O. I., Nahas, M. K., Wang, K., Rampal, R. K., Intlekofer, A. M., Patel, J. L., Krivstov, A. V., Frampton, G. M., Young, L. E., et al. (2016) · Blood · doi:10.1182/blood-2015-08-664649 · Cited by 307 · see citing works

Alternative expression analysis by RNA sequencing

Griffith, M., Griffith, O. L., Mwenifumbo, J. C., Goya, R., Morrissy, A. S., Morin, R. D., Corbett, R., Tang, M., Hou, Y. C., Pugh, T. J., et al. (2010) · Nature Methods · doi:10.1038/nmeth.1503 · Cited by 306 · see citing works

Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes

Bejar, R. L., Levine, R. L., & Ebert, B. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.1175 · Cited by 303 · see citing works

Genome-wide Analysis of Simultaneous GATA1/2, RUNX1, FLI1, and SCL Binding in Megakaryocytes Identifies Hematopoietic Regulators

Tijssen, M. R., Cvejic, A., Joshi, A., Hannah, R., Ferreira, R., Forrai, A., Bellissimo, D. C., Oram, S. H., Smethurst, P. A., Wilson, N. K., et al. (2011) · Developmental Cell · doi:10.1016/j.devcel.2011.04.008 · Cited by 283 · see citing works

Gene expression profiling of CD34+ cells in patients with the 5q− syndrome

Boultwood, J., Pellagatti, A., Cattan, H., Lawrie, C. H., Giagounidis, A. A. N., Malcovati, L., Porta, M. G. D., Jädersten, M., Killick, S. B., Fidler, C., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06833.x · Cited by 151 · see citing works

Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1–CBFβ interaction

Cunningham, L., Finckbeiner, S., Hyde, R. K., Southall, N. T., Marugán, J., Yedavalli, V. R. K., Dehdashti, S., Reinhold, W. C., Alemu, L., Zhao, L., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200037109 · Cited by 133 · see citing works

Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice

Fink, E. C., McConkey, M., Adams, D. N., Haldar, S. D., Kennedy, J. A., Guirguis, A. A., Udeshi, N. D., Mani, D. R., Chen, M., Liddicoat, B., et al. (2018) · Blood · doi:10.1182/blood-2018-05-852798 · Cited by 131 · see citing works

Inhibition of Calpain Blocks Platelet Secretion, Aggregation, and Spreading

Croce, K., Flaumenhaft, R. C., Rivers, M., Furie, B., Furie, B. C., Herman, I. M., & Potter, D. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.51.36321 · Cited by 128 · see citing works

Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant‐negative, or hypomorphic alleles

Matheny, C., Speck, M. E., Cushing, P. R., Zhou, Y., Corpora, T., Regan, M. C., Newman, M. N., Roudaia, L., Speck, C. L., Gu, T.-L., et al. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601568 · Cited by 120 · see citing works

Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes

Sekeres, M. A., Maciejewski, J. P., Giagounidis, A. A. N., Wride, K., Knight, R., Raza, A., & List, A. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.5770 · Cited by 107 · see citing works

Revealing a human p53 universe

Nguyen, T., Grimm, S. A., Bushel, P. R., Li, J., Li, Y., Bennett, B. D., Lavender, C. A., Ward, J. M., Fargo, D. C., Anderson, C. W., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky720 · Cited by 94 · see citing works

A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes

Fang, J., Liu, X., Bolanos, L., Barker, B., Rigolino, C., Cortelezzi, A., Oliva, E. N., Cuzzola, M., Grimes, H. L., Fontanillo, C., et al. (2016) · Nature Medicine · doi:10.1038/nm.4127 · Cited by 83 · see citing works

Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression

Göhring, G., Giagounidis, A. A. N., Büsche, G., Kreipe, H. H., Zimmermann, M., Hellström‐Lindberg, E., Aul, C., & Schlegelberger, B. (2009) · Annals of Hematology · doi:10.1007/s00277-009-0846-z · Cited by 80 · see citing works

Ikaros inhibits megakaryopoiesis through functional interaction with GATA-1 and NOTCH signaling

Malinge, S., Thiollier, C., Chlon, T. M., Doré, L. C., Diebold, L. P., Bluteau, O., Mabialah, V., Vainchenker, W., Dessen, P., Winandy, S., et al. (2013) · Blood · doi:10.1182/blood-2012-08-450627 · Cited by 61 · see citing works

BloodChIP: a database of comparative genome-wide transcription factor binding profiles in human blood cells

Chacon, D., Beck, D., Perera, D., Wong, J., & Pimanda, J. (2013) · Nucleic Acids Res. · doi:10.1093/nar/gkt1036 · Cited by 50 · see citing works

Integrated Genomic Analysis Implicates Haploinsufficiency of Multiple Chromosome 5q31.2 Genes in De Novo Myelodysplastic Syndromes Pathogenesis

Graubert, T. A., Payton, M. A., Shao, J., Walgren, R. A., Monahan, R. S., Frater, J. L., Walshauser, M. A., Martin, M. G., Kasai, Y., & Walter, M. J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004583 · Cited by 50 · see citing works

Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations

Scharenberg, C., Giai, V., Pellagatti, A., Saft, L., Dimitriou, M., Jansson, M., Jädersten, M., Grandien, A., Douagi, I., Neuberg, D. S., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.152025 · Cited by 47 · see citing works

SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q

Talati, C., Sallman, D. A., & List, A. F. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.07.293 · Cited by 7 · see citing works

Dominant-negative IKAROS enhances IL-3-stimulated signaling in wild-type but not BCR-ABL1+ mouse BA/F3 cells

von Palffy, S., Bulaeva, E., Babovic, S., Kannan, N., Knapp, D. J. H. F., Wei, L. L., Eaves, C. J., & Beer, P. A. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.04.004 · Cited by 2 · see citing works

Myelodysplastic Syndromes

Cazzola, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1904794 · Cited by 496 · see citing works

Targeted protein degradation for cancer therapy

Hinterndorfer, M., Spiteri, V. A., Ciulli, A., & Winter, G. E. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00817-8 · Cited by 245 · see citing works

Lenalidomide promotes the development of TP53 -mutated therapy-related myeloid neoplasms

Sperling, A. S., Guerra, V. A., Kennedy, J. A., Yan, Y., Hsu, J. I., Wang, F., Nguyen, A. T., Miller, P. G., McConkey, M. E., Barrios, V. A. Q., et al. (2022) · Blood · doi:10.1182/blood.2021014956 · Cited by 153 · see citing works

Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide

Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137 · see citing works

A clinical transcriptome approach to patient stratification and therapy selection in acute myeloid leukemia

Docking, R., Parker, J., Jädersten, M., Duns, G., Chang, L., Jiang, J., Pilsworth, J. A., Swanson, L., Chan, S. K., Chiu, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22625-y · Cited by 102 · see citing works

Differentiation therapy for myeloid malignancies: beyond cytotoxicity

Stubbins, R. J., & Karsan, A. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00584-3 · Cited by 74 · see citing works

Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation

Yamanaka, S., Furihata, H., Yanagihara, Y., Taya, A., Nagasaka, T., Usui, M., Nagaoka, K., Shoya, Y., Nishino, K., Yoshida, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40385-9 · Cited by 73 · see citing works

Induced protein degradation for therapeutics: past, present, and future

Yoon, H., Rutter, J. C., Li, Y.-D., & Ebert, B. L. (2024) · Journal of Clinical Investigation · doi:10.1172/jci175265 · Cited by 70 · see citing works

IKAROS and MENIN Coordinate Therapeutically Actionable Leukaemogenic Gene Expression in MLL-r Acute Myeloid Leukaemia

Aubrey, B., Cutler, J., Bourgeois, W., Donovan, K., Gu, S., Hatton, C., Perlee, S., Perner, F., Rahnamoun, H., Theall, A., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00366-1 · Cited by 50 · see citing works

Targeting cereblon in hematologic malignancies

Fuchs, O. (2023) · Blood Reviews · doi:10.1016/j.blre.2022.100994 · Cited by 55 · see citing works

SLC44A2 regulates vascular smooth muscle cell phenotypic switching and aortic aneurysm

Song, T.-Y., Zhao, S., Luo, S.-S., Chen, C., Liu, X., Wu, X., Sun, Z., Cao, J., Wang, Z., Wang, Y., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci173690 · Cited by 43 · see citing works

Mechanisms of lenalidomide sensitivity and resistance

Martínez-Høyer, S., & Karsan, A. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.09.196 · Cited by 45 · see citing works

Developing a classification of hematologic neoplasms in the era of precision medicine

Cazzola, M., & Sehn, L. H. (2022) · Blood · doi:10.1182/blood.2022015849 · Cited by 42 · see citing works

Targeting the Microenvironment in MDS: The Final Frontier

Teodorescu, P., Paşca, S., Dima, D. M., Tomuleasa, C., & Ghiaur, G. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01044 · Cited by 25 · see citing works

Loss of 5q in myeloid malignancies – A gain in understanding of biological and clinical consequences

Venugopal, S., Mascarenhas, J. O., & Steensma, D. P. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100735 · Cited by 25 · see citing works

TIRAP drives myelosuppression through an Ifnγ–Hmgb1 axis that disrupts the endothelial niche in mice

Gopal, A., Ibrahim, R., Fuller, M., Umlandt, P., Parker, J., Tran, J., Chang, L., Wegrzyn-Woltosz, J., Lam, J., Li, J., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20200731 · Cited by 20 · see citing works

Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML

Drulă, R., Iluta, S., Gulei, D., Iuga, C. A., Dima, D. M., Ghiaur, G., Buzoianu, A. D., Ciechanover, A. J., & Tomuleasa, C. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.100971 · Cited by 20 · see citing works

Helios represses megakaryocyte priming in hematopoietic stem and progenitor cells

Cova, G., Taroni, C., Deau, M.-C., Cai, Q., Mittelheisser, V., Philipps, M., Jung, M., Cerciat, M., Le Gras, S., Thibault-Carpentier, C., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20202317 · Cited by 17 · see citing works

Single cell RNA sequencing improves the next generation of approaches to AML treatment: challenges and perspectives

Khosroabadi, Z., Azaryar, S., Dianat‐Moghadam, H., Amoozgar, Z., & Sharifi, M. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01085-w · Cited by 18 · see citing works

Prognostic effect of RUNX1 mutations in myelodysplastic syndromes: a meta-analysis

He, W., Zhao, C., & Hu, H. (2020) · Hematology · doi:10.1080/16078454.2020.1858598 · Cited by 16 · see citing works

Key regulators of sensitivity to immunomodulatory drugs in cancer treatment

Wang, S., Li, Z., & Gao, S. (2021) · Biomarker Research · doi:10.1186/s40364-021-00297-6 · Cited by 17 · see citing works

SLC44A2-mediated phenotypic switch of vascular smooth muscle cells contributes to aortic aneurysm

Xing, M., Chen, W., Ji, Y., & Song, W. (2024) · Journal of Clinical Investigation · doi:10.1172/jci183527 · Cited by 15 · see citing works

Myelodysplastic syndromes: Biological and therapeutic consequences of the evolving molecular aberrations landscape

Schwind, S., Jentzsch, M., Kubasch, A. S., Metzeler, K. H., & Platzbecker, U. (2021) · Neoplasia · doi:10.1016/j.neo.2021.09.002 · Cited by 14 · see citing works

LILRB4 regulates multiple myeloma development through STAT3-PFKFB1 pathway

Xie, L., Chen, C., Zhang, T., Yang, W., Zheng, D., Cao, L., Yuan, J., Xu, Y., Zhang, Y., Liu, L., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06883-4 · Cited by 11 · see citing works

The RUNX Family, a Novel Multifaceted Guardian of the Genome

Dutta, B., & Osato, M. (2023) · Cells · doi:10.3390/cells12020255 · Cited by 11 · see citing works

Chemoresistance in acute myeloid leukemia: An alternative single‐cell RNA sequencing approach

Cheng, P., Hsiao, T., Chen, C., Hung, M., Jhan, P., Lee, L., Wu, T., Tsai, J., & Teng, C. J. (2023) · Hematological Oncology · doi:10.1002/hon.3129 · Cited by 11 · see citing works

Role of microRNAs and their downstream target transcription factors in zebrafish thrombopoiesis

Qaryoute, A. A., Fallatah, W., Dhinoja, S., Raman, R., & Jagadeeswaran, P. (2023) · Scientific Reports · doi:10.1038/s41598-023-42868-7 · Cited by 10 · see citing works

Preclinical evaluation of eltrombopag in a PDX model of myelodysplastic syndromes

Schmitt, N., Jann, J.-C., Altrock, E., Flach, J., Danner, J., Uhlig, S., Streuer, A., Knaflic, A., Riabov, V., Xu, Q., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01327-w · Cited by 10 · see citing works

TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia

Rahmé, R., Braun, T., Manfredi, J. J., & Fenaux, P. (2023) · Biomedicines · doi:10.3390/biomedicines11041152 · Cited by 9 · see citing works

A precision medicine approach to the myelodysplastic syndrome with isolated deletion 5q, 50 years after its discovery

Roncador, M., Bernard, E., Hasserjian, R. P., Boultwood, J., Elena, C., Gallì, A., Gurnari, C., Mecucci, C., Michaux, L., Mittelman, M., et al. (2025) · Blood · doi:10.1182/blood.2025028619 · Cited by 8 · see citing works

A Single-Run Next-Generation Sequencing (NGS) Assay for the Simultaneous Detection of Both Gene Mutations and Large Chromosomal Abnormalities in Patients with Myelodysplastic Syndromes (MDS) and Related Myeloid Neoplasms

Liquori, A., Lesende‐Rodriguez, I., Palomo, L., Avetisyan, G., Ibáñez, M., González-Romero, E., Boluda-Navarro, M., Morote-Faubel, M., García-Ruiz, C., Martínez-Valiente, C., et al. (2021) · Cancers · doi:10.3390/cancers13081947 · Cited by 8 · see citing works

Molecular glues: A new path to the world of the unattainable

Khaledian, M., Sheikh, H., Babaei, F., Divsalar, A., Gharshasbi, M., Ottmann, C., Haertlé, T., Saboury, A. A., & Rasouli, M. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.148861 · Cited by 6 · see citing works

Leukemia-initiating HSCs in chronic lymphocytic leukemia reveal clonal leukemogenesis and differential drug sensitivity

Chiang, C., Hu, E. Y., Chang, L., Labanowska, J. M., Zapolnik, K., Mo, X. M., Shi, J., Doong, T.-J., Lozanski, A., Yan, P. S., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111115 · Cited by 6 · see citing works

THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION

Fabiani, E., Falconi, G., Cristiano, A., Hajrullaj, H., Falconi, G., Leone, G. G. M., & Voso, M. T. (2023) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2023.064 · Cited by 6 · see citing works

Deciphering the Key Pharmacological Pathways and Targets of Yisui Qinghuang Powder That Acts on Myelodysplastic Syndromes Using a Network Pharmacology‐Based Strategy

Han, Z., Song, L., Qi, K., Ding, Y., Wei, M., & Yongcun, J. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/8877295 · Cited by 4 · see citing works

Del(5q) and inv(3) in myelodysplastic syndrome: A rare case report

Liang, H., Luo, X., Zhang, Y., & Liu, B. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i11.3601 · Cited by 3 · see citing works

Myelodysplastic Syndrome

Fuchs, O. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00046-9 · Cited by 2 · see citing works

Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm

Gharaee, N., Wegrzyn-Woltosz, J., Jiang, J., Akhade, V. S., Bridgers, J., Stubbins, R. J., Hiwase, D., Kutyna, M., Chan, O., Komrokji, R. S., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02537-2 · Cited by 2 · see citing works

Clinical and Biological Insights into Myelodysplastic Neoplasms Associated with Deletions of Chromosome 5q Region

Testa, U., Castelli, G., & Pelosi, E. (2025) · Hematology Reports · doi:10.3390/hematolrep17060067 · Cited by 1 · see citing works

Role of MicroRNAs and Their Downstream Targets in Zebrafish Thrombopoiesis

Qaryoute, A. A. (2023) · doi:10.12794/metadc2137555

Targeted protein degradation using thalidomide and its derivatives

Yamanaka, S. (2024) · Translational and Regulatory Sciences · doi:10.33611/trs.2024-007

Lenalidomide Exposure and TP53-Mutated Myelodysplastic Syndromes/Neoplasms

Katamesh, B., & Shallis, R. M. (2026) · Current Oncology · doi:10.3390/curroncol33090506

3108 – MOLECULAR MECHANISMS OF LENALIDOMIDE RESISTANCE IN DEL(5Q) MYELODYSPLASTIC SYNDROMES

Martínez-Høyer, S., Deng, Y., Parker, J., Jiang, J., Docking, R., Mo, A., Gharaee, N., Jädersten, M., Kulasekararaj, A. G., Malcovati, L., et al. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.09.120

Mechanisms of Resistance to Lenalidomide in Del(5q) Myelodysplastic Syndrome Patients

Martínez-Høyer, S., Docking, R., Chan, S. K., Jädersten, M., Parker, J., & Karsan, A. (2015) · Blood · doi:10.1182/blood.v126.23.5228.5228 · Cited by 6 · see citing works

Resistance to Lenalidomide in Del(5q) MDS Is Mediated By Inhibition of Drug-Induced Megakaryocytic Differentiation

Martínez-Høyer, S., Mo, A., Deng, D., Jiang, J., Docking, R., Li, J., Chan, S. K., Umlandt, P., Fuller, M. E., Jädersten, M., et al. (2018) · Blood · doi:10.1182/blood-2018-176 · Cited by 2 · see citing works

Overcoming lenalidomide resistance in del(5q) myelodysplastic syndrome

Gharaee, N. (2024) · cIRcle (University of British Columbia) · doi:10.14288/1.0415838 · Cited by 1 · see citing works

A Calcium-Dependent Pathway Determines Response to Lenalidomide in Del(5q) Myelodysplastic Syndromes

Fang, J., Liu, X., Bolanos, L. C., Barker, B., Rigolino, C., Cortelezzi, A., Olíva, E. N., MacBeth, K. J., Komurov, K., & Starczynowski, D. T. (2014) · Blood · doi:10.1182/blood.v124.21.1898.1898